Giulia Pranteda
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Giulia Pranteda has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
- Marta Carlesimo
U.O.C. Dermatology, II Unit University of Rome ‘Sapienza’, Rome, Italy
12 shared publications - Ugo Bottoni
University Magna Graecia
12 shared publications - Alfredo Rossi
Division of Dermatology, Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy
10 shared publications - Valentina Garelli
Department of Plastic and Regenerative Surgery San Gallicano Dermatological Institute IRCCS Rome Italy
9 shared publications - Guglielmo Pranteda
Department of Dermatology, La Sapienza University, Rome, Italy
4 shared publications M Grimaldi
4 shared publications
Latest Publications
- 1 March 2020
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
Erythema elevatum diutinum of the hand: a peculiar case, successfully treated with tetracyclines
Article: Erythema elevatum diutinum of the hand: a peculiar case, successfully treated with tetracyclines - Giornale Italiano di Dermatologia e Venereologia 2020 Mar 04 - Minerva Medica - Journals
- 1 March 2020
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
Erythema elevatum diutinum of the hand: a peculiar case, successfully treated with tetracyclines
Article: Erythema elevatum diutinum of the hand: a peculiar case, successfully treated with tetracyclines - Giornale Italiano di Dermatologia e Venereologia 2020 Mar 04 - Minerva Medica - Journals
- 1 December 2019
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 154 (6) , 732-734
Sannino-Barduagni-Bottoni Syndrome
- 1 December 2019
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 154 (6) , 732-734
Sannino-Barduagni-Bottoni Syndrome
- 1 January 2019
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 154 (1) , 96-98
Kerion mimicking an erosive pustular dermatosis of the scalp
- 1 January 2019
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 154 (1) , 96-98
Kerion mimicking an erosive pustular dermatosis of the scalp
- 27 July 2018
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (2) , E58-E59
The use of PRP (platelet‐rich plasma) in patients affected by genital lichen sclerosus: clinical analysis and results
- 27 July 2018
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 33 (2) , E58-E59
The use of PRP (platelet‐rich plasma) in patients affected by genital lichen sclerosus: clinical analysis and results
- 1 March 2018
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 153 (2) , 285-286
Carbamazepine-induced necrotizing leukocytoclastic vasculitis with a 20-year latency
- 1 March 2018
- Published by Edizioni Minerva Medica in Italian Journal of Dermatology and Venereology
- Vol. 153 (2) , 285-286
Carbamazepine-induced necrotizing leukocytoclastic vasculitis with a 20-year latency
- 1 July 2017
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 77 (1) , 172-174
Unusual patterns of presentation of frontal fibrosing alopecia: A clinical and trichoscopic analysis of 98 patients
- 1 July 2017
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 77 (1) , 172-174
Unusual patterns of presentation of frontal fibrosing alopecia: A clinical and trichoscopic analysis of 98 patients
- 29 June 2017
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 29 (2) , 149-151
A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia
Background: Androgenetic alopecia (AGA) is a common form of scalp hair loss that affects up to 50% of males between 18 and 40 years old. Several molecules are commonly used for the treatment of AGA, acting on different steps of its pathogenesis (Minoxidil, Finasteride, Serenoa repens) and show some side effects. In literature, on the basis of hypertrichosis observed in patients treated with analogues of prostaglandin PGF2a, it was supposed that prostaglandins would have an important role in the hair growth: PGE and PGF2a play a positive role, while PGD2 a negative one. Objective: We carried out a pilot study to evaluate the efficacy of topical cetirizine versus placebo in patients with AGA. Patients and methods: A sample of 85 patients was recruited, of which 67 were used to assess the effectiveness of the treatment with topical cetirizine, while 18 were control patients. Results: We found that the main effect of cetirizine was an increase in total hair density, terminal hair density and diameter variation from T0 to T1, while the vellus hair density shows an evident decrease. The use of a molecule as cetirizine, with no notable side effects, makes possible a good compliance by patients. Conclusion: Our results have shown that topical cetirizine 1% is responsible for a significant improvement of the initial framework of AGA.
- 29 June 2017
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 29 (2) , 149-151
A preliminary study on topical cetirizine in the therapeutic management of androgenetic alopecia
Background: Androgenetic alopecia (AGA) is a common form of scalp hair loss that affects up to 50% of males between 18 and 40 years old. Several molecules are commonly used for the treatment of AGA, acting on different steps of its pathogenesis (Minoxidil, Finasteride, Serenoa repens) and show some side effects. In literature, on the basis of hypertrichosis observed in patients treated with analogues of prostaglandin PGF2a, it was supposed that prostaglandins would have an important role in the hair growth: PGE and PGF2a play a positive role, while PGD2 a negative one. Objective: We carried out a pilot study to evaluate the efficacy of topical cetirizine versus placebo in patients with AGA. Patients and methods: A sample of 85 patients was recruited, of which 67 were used to assess the effectiveness of the treatment with topical cetirizine, while 18 were control patients. Results: We found that the main effect of cetirizine was an increase in total hair density, terminal hair density and diameter variation from T0 to T1, while the vellus hair density shows an evident decrease. The use of a molecule as cetirizine, with no notable side effects, makes possible a good compliance by patients. Conclusion: Our results have shown that topical cetirizine 1% is responsible for a significant improvement of the initial framework of AGA.
- 1 June 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 86 (3) , 249-251
Vascular Psoriasis Area Severity Index: A dermoscopic standard technique for assessing severity psoriasis and therapeutic management
- 1 June 2017
- Published by Elsevier in Journal of Dermatological Science
- Vol. 86 (3) , 249-251
Vascular Psoriasis Area Severity Index: A dermoscopic standard technique for assessing severity psoriasis and therapeutic management
- 2 February 2017
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 16 (4) , 537-541
Chemotherapy‐induced alopecia management: Clinical experience and practical advice
Summary: Background: Chemotherapy‐induced alopecia (CIA) is probably one of the most shocking aspects for oncological patients and underestimated by physicians. Among hair loss risk factors, there are treatment‐related aspects such as drug dose, administration regimen, and exposure to X‐rays, but also patient‐related characteristics. To the best of our knowledge, no guidelines are available about CIA management.Aims and methods: With this study, based on literature background and our clinical experience, we would like to propose a list of actions in order to estimate the risk of hair loss before starting chemotherapy and to manage this condition before, during, and after drug administration and to create a sort of practical guide for dermatologists and oncologists.Results and conclusion: There is an urgent need for prospective studies to clarify the mechanistic basis of alopecia associated with these drugs and consequently to design evidence‐based management strategies.
- 2 February 2017
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 16 (4) , 537-541
Chemotherapy‐induced alopecia management: Clinical experience and practical advice
Summary: Background: Chemotherapy‐induced alopecia (CIA) is probably one of the most shocking aspects for oncological patients and underestimated by physicians. Among hair loss risk factors, there are treatment‐related aspects such as drug dose, administration regimen, and exposure to X‐rays, but also patient‐related characteristics. To the best of our knowledge, no guidelines are available about CIA management.Aims and methods: With this study, based on literature background and our clinical experience, we would like to propose a list of actions in order to estimate the risk of hair loss before starting chemotherapy and to manage this condition before, during, and after drug administration and to create a sort of practical guide for dermatologists and oncologists.Results and conclusion: There is an urgent need for prospective studies to clarify the mechanistic basis of alopecia associated with these drugs and consequently to design evidence‐based management strategies.
- Open Access
- 1 January 2017
- Published by Scitechnol Biosoft Pvt. Ltd. in Australasian Medical Journal
- Vol. 10 (08)
AN UNUSUAL CASE OF NEONATAL MASTOCYTOMA
- 1 January 2017
- Published by Scitechnol Biosoft Pvt. Ltd. in Australasian Medical Journal
- Vol. 10 (08)
Open AccessAN UNUSUAL CASE OF NEONATAL MASTOCYTOMA